Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 18/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 17/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL935077 | 1.00 | SLC6A4 (0.47) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL967230 | 1.00 | SLC6A4 (0.47) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL967231 | 1.00 | SLC6A4 (0.47) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL966202 | 0.90 | SLC6A4 (0.45) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL964451 | 0.90 | SLC6A4 (0.45) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL964448 | 0.90 | SLC6A4 (0.45) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL966204 | 0.90 | SLC6A4 (0.45) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL935256 | 0.89 | SLC6A4 (0.60) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL964952 | 0.89 | SLC6A4 (0.60) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL964951 | 0.89 | SLC6A4 (0.60) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853255-B2 | 3-phenoxymethylpyrrolidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2456436-B1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | THERAVANCE INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-20130237581-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-8455665-B2 | 3-phenoxymethylpyrrolidine compounds | THERAVANCE, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20120309985-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-8273786-B2 | 3-phenoxymethylpyrrolidine compounds | THERAVANCE, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2456436-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | Theravance, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20110021597-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-01-27 | — | — | US | disclosed |
| WO-2011011231-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021597-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | HTR6, SLC6A4, SLC6A2 | SLC6A4 2/4885SLC6A2 3/4885SLC6A3 6/4885 |
| US-20130237581-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | HTR6, SLC6A4, SLC6A2 | SLC6A4 2/4885SLC6A2 3/4885SLC6A3 6/4885 |
| US-20120309985-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | HTR6, SLC6A4, SLC6A2 | SLC6A4 2/4885SLC6A2 3/4885SLC6A3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.